MCID: PNC015
MIFTS: 39

Pancreatic Acinar Cell Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Acinar Cell Adenocarcinoma

MalaCards integrated aliases for Pancreatic Acinar Cell Adenocarcinoma:

Name: Pancreatic Acinar Cell Adenocarcinoma 12 15
Pancreatic Acinar Cell Carcinoma 12 17
Acinar Cell Adenocarcinoma of the Pancreas 70

Classifications:



External Ids:

Disease Ontology 12 DOID:5742
NCIt 50 C7977
SNOMED-CT 67 783771003
UMLS 70 C0279661

Summaries for Pancreatic Acinar Cell Adenocarcinoma

Disease Ontology : 12 A pancreatic adenocarcinoma that has material basis in cells with morphological resemblance to acinar cells and is associated with increased serum lipase.

MalaCards based summary : Pancreatic Acinar Cell Adenocarcinoma, also known as pancreatic acinar cell carcinoma, is related to acinar cell carcinoma and pancreatoblastoma, and has symptoms including abdominal pain, pruritus and icterus. An important gene associated with Pancreatic Acinar Cell Adenocarcinoma is SERPINA3 (Serpin Family A Member 3), and among its related pathways/superpathways are Oncogenic MAPK signaling and MNAR-PELP1 and Estrogen Receptor Interaction. The drugs Fluorouracil and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include pancreas, colon and breast, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Pancreatic Acinar Cell Adenocarcinoma

Diseases related to Pancreatic Acinar Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 242)
# Related Disease Score Top Affiliating Genes
1 acinar cell carcinoma 31.1 SERPINA3 REG1A CPA1 CHGA BCL10 AFP
2 pancreatoblastoma 30.4 SYP SERPINA3 CHGA AFP
3 islet cell tumor 30.4 SYP SERPINA3 CHGA
4 neuroendocrine tumor 30.0 SYP KRT19 HRAS CHGA
5 neuroendocrine carcinoma 29.9 SYP KRT19 CHGA
6 pancreatic cancer 28.7 SERPINA3 REG1A KRT19 KRAS HRAS CPA1
7 acinar cell carcinoma of pancreas 11.5
8 rare tumor 10.6
9 panniculitis 10.5
10 pancreatic ductal adenocarcinoma 10.4
11 mixed hepatoblastoma 10.4 SERPINA3 AFP
12 scrotum neoplasm 10.4 SERPINA3 AFP
13 pancreas sarcoma 10.4 SERPINA3 AFP
14 thymus sarcomatoid carcinoma 10.3 SYP AFP
15 pineal region teratoma 10.3 SYP AFP
16 testicular malignant germ cell cancer 10.3 SERPINA3 AFP
17 liver sarcoma 10.3 SERPINA3 AFP
18 primary hepatic neuroendocrine carcinoma 10.3 SYP CHGA
19 rectum neuroendocrine neoplasm 10.3 SYP AFP
20 esophageal neuroendocrine tumor 10.3 SYP CHGA
21 auditory system benign neoplasm 10.3 SYP CHGA
22 auditory system cancer 10.3 SYP CHGA
23 vulvar eccrine porocarcinoma 10.3 SYP CHGA
24 pancreatic serous cystadenocarcinoma 10.3 SYP CHGA
25 cauda equina neoplasm 10.3 SYP CHGA
26 gastrointestinal neuroendocrine benign tumor 10.3 SYP CHGA
27 appendix carcinoid tumor 10.3 SYP CHGA
28 carotid body cancer 10.3 SYP CHGA
29 vaginal tubulovillous adenoma 10.3 SYP CHGA
30 mixed ductal-endocrine carcinoma 10.3 SYP CHGA
31 laryngeal small cell carcinoma 10.3 SYP CHGA
32 gallbladder small cell carcinoma 10.3 SYP CHGA
33 ureter small cell carcinoma 10.3 SYP CHGA
34 papillary thymic adenocarcinoma 10.3 SYP CHGA
35 middle ear adenoma 10.3 SYP CHGA
36 adult teratoma 10.3 CHGA AFP
37 urinary bladder small cell neuroendocrine carcinoma 10.3 SYP CHGA
38 gastric small cell carcinoma 10.3 SYP CHGA
39 breast papillary carcinoma 10.3 SYP CHGA
40 extracranial neuroblastoma 10.3 SYP CHGA
41 sensory organ benign neoplasm 10.3 SYP CHGA
42 cervical neuroblastoma 10.3 SYP CHGA
43 laryngeal neuroendocrine tumor 10.3 SYP CHGA
44 gastric neuroendocrine neoplasm 10.3 SYP CHGA
45 ovarian large-cell neuroendocrine carcinoma 10.3 SYP CHGA
46 gastric hemangioma 10.3 SYP CHGA
47 subependymoma 10.3 SYP CHGA
48 pineocytoma 10.3 SYP CHGA
49 obstructive jaundice 10.3
50 pancreatic adenocarcinoma 10.3

Graphical network of the top 20 diseases related to Pancreatic Acinar Cell Adenocarcinoma:



Diseases related to Pancreatic Acinar Cell Adenocarcinoma

Symptoms & Phenotypes for Pancreatic Acinar Cell Adenocarcinoma

UMLS symptoms related to Pancreatic Acinar Cell Adenocarcinoma:


abdominal pain; pruritus; icterus

GenomeRNAi Phenotypes related to Pancreatic Acinar Cell Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-106 9.4 CELA1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-117 9.4 AFP CELA1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.4 KRAS
4 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.4 AFP
5 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.4 KRAS
6 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.4 CELA1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-48 9.4 AFP
8 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.4 KRAS
9 Increased shRNA abundance (Z-score > 2) GR00366-A-69 9.4 CELA1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-71 9.4 CELA1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-89 9.4 AFP

MGI Mouse Phenotypes related to Pancreatic Acinar Cell Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.61 AFP BCL10 CHGA CPA1 HRAS KRAS
2 neoplasm MP:0002006 9.1 AFP FUT8 HRAS KRAS KRT19 TOM1L2

Drugs & Therapeutics for Pancreatic Acinar Cell Adenocarcinoma

Drugs for Pancreatic Acinar Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 3 51-21-8 3385
2
Gemcitabine Approved Phase 3 95058-81-4 60750
3
Pancrelipase Approved, Investigational Phase 3 53608-75-6
4
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
5 pancreatin Phase 3
6 Anti-Infective Agents Phase 3
7 Immunosuppressive Agents Phase 3
8 Antiviral Agents Phase 3
9 Antimetabolites Phase 3
10 Immunologic Factors Phase 3
11 Protein Kinase Inhibitors Phase 3
12
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
13
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
14
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
15
Metformin Approved Phase 2 657-24-9 4091 14219
16
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
17
leucovorin Approved Phase 2 58-05-9 6006
18
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
19
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
20
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
21
Ifosfamide Approved Phase 2 3778-73-2 3690
22
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
23
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
24
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
25 Bryostatin 1 Investigational Phase 2 83314-01-6
26 Adjuvants, Immunologic Phase 2
27 Angiogenesis Inhibitors Phase 2
28 Hypoglycemic Agents Phase 2
29 Vitamin B9 Phase 2
30 Nutrients Phase 2
31 Trace Elements Phase 2
32 Micronutrients Phase 2
33 Vitamin B Complex Phase 2
34 Vitamins Phase 2
35 Antidotes Phase 2
36 Folate Phase 2
37 Calcium, Dietary Phase 2
38 Protective Agents Phase 2
39 Hormones Phase 2
40 topoisomerase I inhibitors Phase 2
41 Folfirinox Phase 2
42 Tubulin Modulators Phase 1, Phase 2
43 Albumin-Bound Paclitaxel Phase 1, Phase 2
44 Antimitotic Agents Phase 1, Phase 2
45 Antibiotics, Antitubercular Phase 2
46 Mitomycins Phase 2
47 Alkylating Agents Phase 2
48 Anti-Bacterial Agents Phase 2
49
Isophosphamide mustard Phase 2 100427
50
Calcium Nutraceutical Phase 2 7440-70-2 271

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 European Study Group For Pancreatic Cancer - Trial 3 Completed NCT00058201 Phase 3 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
2 A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma Active, not recruiting NCT01013649 Phase 3 Capecitabine;Chemotherapy;Erlotinib Hydrochloride;Fluorouracil;Gemcitabine Hydrochloride
3 A Phase II Study Of Triapine For Advanced Adenocarcinoma Of The Pancreas Completed NCT00085371 Phase 2 triapine
4 A Phase II Study of Sequential Paclitaxel and Bryostatin-1 for Patients With Advanced Pancreatic Cancer Completed NCT00031694 Phase 2 paclitaxel;bryostatin 1
5 A Multicenter, Open-Label, Randomized, Phase II Trial of Adjuvant Dasatinib Plus Gemcitabine Versus Single-Agent Gemcitabine in Patients With Resected Pancreatic Adenocarcinoma Completed NCT01234935 Phase 2 dasatinib;gemcitabine hydrochloride
6 A Phase II Study of Sunitinib Malate (SU11248, NSC #736511, IND #74,019) in Patients With Previously Treated Pancreatic Adenocarcinoma With Measurable Metastatic Disease Following Progression on Front-Line Gemcitabine-Based Therapy Completed NCT00397787 Phase 2 sunitinib malate
7 A Phase II Study of Metformin Plus Modified FOLFOX 6 in Patients With Metastatic Pancreatic Cancer Completed NCT01666730 Phase 2 metformin hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
8 Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs mFOLFOX in Patients With Metastatic Pancreatic Cancer After Prior Chemotherapy Completed NCT01658943 Phase 2 Akt Inhibitor MK2206;Fluorouracil;Oxaliplatin;Selumetinib
9 A 2-arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysin) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer Completed NCT01280058 Phase 2 Carboplatin;Paclitaxel
10 Phase II Study of Peri-Operative Modified Folfirinox in Localized Pancreatic Cancer Recruiting NCT02047474 Phase 2 oxaliplatin;leucovorin calcium;irinotecan hydrochloride;fluorouracil
11 Phase Ib Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330), Gemcitabine and Nab-Paclitaxel and Phase II Study of Gemcitabine and Selinexor in Patients With Metastatic Pancreatic Cancer Recruiting NCT02178436 Phase 1, Phase 2 gemcitabine hydrochloride;Selinexor;Nab paclitaxel
12 Mitomycin and Ifosfamide (MI) as Salvage Therapy for Metastatic Pancreatic Adenocarcinoma: a Phase II Study. Terminated NCT00967291 Phase 2 ifosfamide;mitomycin C
13 A Phase II Study of Bortezomib in Combination With Carboplatin in Patients With Metastatic Pancreatic Cancer Terminated NCT00416793 Phase 2 bortezomib;carboplatin
14 A Phase I/II Study of Sorafenib and Everolimus in Patients With Advanced Solid Tumors and Gemcitabine-Refractory Metastatic Pancreatic Cancer Completed NCT00981162 Phase 1 sorafenib tosylate;everolimus
15 A Pilot Study: Open-Label Clinical Trial of CPI-613 in Patients With Metastatic Pancreatic Adenocarcinoma and Poor Performance Status Completed NCT01839981 Phase 1 6,8-bis(benzylthio)octanoic acid
16 Open-label, Single-center, Non-randomized, Phase I, Dose-ranging Study of Endoscopic Ultrasound (EUS) Guided Photodynamic Therapy (PDT) With Photofrin® in Locally Advanced Pancreatic Cancer Completed NCT01770132 Phase 1 porfimer sodium;gemcitabine hydrochloride
17 A Genotype-guided Dosing Study of mFOLFIRINOX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies Completed NCT01643499 Phase 1 oxaliplatin;irinotecan hydrochloride;leucovorin calcium;fluorouracil
18 Phase I Trial of The Combination of Vismodegib and Sirolimus Completed NCT01537107 Phase 1 vismodegib;sirolimus
19 A Phase I Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer and Good Performance Status Active, not recruiting NCT01835041 Phase 1 6,8-bis(benzylthio)octanoic acid;oxaliplatin;leucovorin calcium;irinotecan hydrochloride;fluorouracil
20 Phase I Study of the Combination of MLN8237 and Gemcitabine in Advanced Solid Tumors With Emphasis on Pancreatic Cancer Active, not recruiting NCT01924260 Phase 1 alisertib;gemcitabine
21 RT-054: A Phase I Study of Neoadjuvant Hypofractionated Chemoradiation Plus Radiosurgical Boost for Patients With Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer Terminated NCT01739439 Phase 1 gemcitabine hydrochloride
22 A First Time in Human Phase I Imaging Study of iRGD in Patients With Advanced Breast and Pancreas Cancer Withdrawn NCT01741597 Phase 1
23 Neoadjuvant FOLFIRINOX and Chemoradiation Followed by Definitive Surgery and Postoperative Gemcitabine for Patients With Borderline Resectable Pancreatic Adenocarcinoma: An Intergroup Single-Arm Pilot Study Completed NCT01821612 Early Phase 1 oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;gemcitabine
24 A Pilot Trial of Stereotactic Body Radiation Therapy and Metformin for Borderline-Resectable and Locally-Advanced Pancreatic Adenocarcinomas Completed NCT02153450 Early Phase 1 metformin hydrochloride

Search NIH Clinical Center for Pancreatic Acinar Cell Adenocarcinoma

Genetic Tests for Pancreatic Acinar Cell Adenocarcinoma

Anatomical Context for Pancreatic Acinar Cell Adenocarcinoma

MalaCards organs/tissues related to Pancreatic Acinar Cell Adenocarcinoma:

40
Pancreas, Colon, Breast, Skin

Publications for Pancreatic Acinar Cell Adenocarcinoma

Articles related to Pancreatic Acinar Cell Adenocarcinoma:

(show top 50) (show all 185)
# Title Authors PMID Year
1
Pancreatic Acinar Cell Carcinoma with Concomitant Bullous Pemphigoid. 61
33757939 2021
2
Clinical characteristics and treatment analysis of pancreatic acinar cell carcinoma: A single institutional comparison to pancreatic ductal adenocarcinoma. 61
33611029 2021
3
Multicenter Retrospective Analysis of Chemotherapy for Advanced Pancreatic Acinar Cell Carcinoma: Potential Efficacy of Platinum- and Irinotecan-Containing Regimens. 61
33370026 2021
4
Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature. 61
33406492 2021
5
Efficacy of chemotherapy combined with toripalimab in PD-L1-positive and high tumor mutation burden pancreatic acinar cell carcinoma: case report. 61
33345750 2020
6
Rare case of acinar cell carcinoma with multiple lesions in the pancreas. 61
33319067 2020
7
Robot-assisted combined pancreatectomy/hepatectomy for metastatic pancreatic acinar cell carcinoma: case report and review of the literature. 61
32583372 2020
8
Computed tomography features of acinar cell carcinoma of the pancreas. 61
32146131 2020
9
Pancreatic acinar cell carcinoma with a ductal adenocarcinoma component: a case report and analysis of the histogenesis of the tumor. 61
32891173 2020
10
RAF1 rearrangements are common in pancreatic acinar cell carcinomas. 61
32358589 2020
11
Carboxypeptidase A1 and regenerating islet-derived 1α as new markers for pancreatic acinar cell carcinoma. 61
32702400 2020
12
Successful BRAF/MEK inhibition in a patient with BRAFV600E-mutated extrapancreatic acinar cell carcinoma. 61
32843432 2020
13
Patients With Acinar Cell Carcinoma of the Pancreas After 2005: A Large Population Study. 61
32541633 2020
14
Lipase hypersecretion syndrome: A rare cutaneous manifestation of advanced pancreatic acinar cell carcinoma. 61
32477543 2020
15
RET gene rearrangements occur in a subset of pancreatic acinar cell carcinomas. 61
31558784 2020
16
Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation: A case report. 61
32337198 2020
17
Clinically resectable acinar cell carcinoma of the pancreas: Is there a benefit to adjuvant systemic therapy? 61
31677782 2020
18
Corrigendum to "Pancreatic acinar cell carcinoma-literature review and case report of a 56-year-old man presenting with abdominal pain" [Radiol Case Rep 15 (2020) 39-43]. 61
32071654 2020
19
Pancreatic acinar cell carcinoma--literature review and case report of a 56-year-old man presenting with abdominal pain. 61
31737144 2020
20
The contemporary trend in worsening prognosis of pancreatic acinar cell carcinoma: A population-based study. 61
33332471 2020
21
The surgical management of metastatic pancreatic acinar cell carcinoma and associated pancreatic panniculitis-A case report and literature review. 61
33207427 2020
22
Prognostic Factors of Acinar Cell Carcinomas: A Study of 44 Patients. 61
31688607 2019
23
Paraneoplastic Cast Nephropathy Associated With Pancreatic Mixed Acinar-Neuroendocrine Carcinoma: A Case Report. 61
30952487 2019
24
Pancreatitis, Panniculitis, and Polyarthritis Syndrome Simulating Cellulitis and Gouty Arthritis. 61
31554034 2019
25
Lipase hypersecretion syndrome: A distinct form of paraneoplastic syndrome specific to pancreatic acinar carcinomas. 61
31300257 2019
26
MR imaging features of pancreatic acinar cell carcinoma. 61
30846400 2019
27
Underutilization of surgical resection in patients with pancreatic acinar cell carcinoma. 61
30514625 2019
28
Inconsistency Between Contrast-Enhanced CT and Bone Scintigraphy in Revealing Radiation Nephritis. 61
31021909 2019
29
Typical CT and MRI Features of Pancreatic Acinar Cell Carcinoma: Main teaching point: Typical imaging features of pancreatic acinar cell carcinoma are relatively large, with a well-defined margin, exophytic growth, and heterogeneous enhancement. 61
31276097 2019
30
Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutations: a case report and literature review. 61
31002019 2019
31
Pancreatic Acinar Cell Carcinoma with Multiple Liver Metastases Effectively Treated by S-1 Chemotherapy. 61
30101903 2018
32
[A Case of Pancreatic Acinar Cell Carcinoma in a Young Woman without Recurrence after Systemic Chemotherapy Using S-1]. 61
30692449 2018
33
Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report. 61
30407325 2018
34
Pancreatic acinar cell carcinoma-case report and literature review. 61
30409114 2018
35
Prevention of pancreatic acinar cell carcinoma by Roux-en-Y Gastric Bypass Surgery. 61
30305629 2018
36
Surgical resection of hepatic and rectal metastases of pancreatic acinar cell carcinoma (PACC): a case report. 61
30075727 2018
37
Pancreatic acinar cell carcinoma-induced panniculitis. 61
30128347 2018
38
Pancreatic panniculitis as a presentation symptom of acinar cell carcinoma. 61
29527901 2018
39
Monoclonal Antibody Production Against Vimentin by Whole Cell Immunization in a Mouse Model. 61
30805388 2018
40
[Clinicopathologic characterisitics of pancreatic acinar cell carcinomas]. 61
29690667 2018
41
BRAF gene rearrangements can be identified by FISH studies in pancreatic acinar cell carcinoma. 61
29506751 2018
42
EGFR amplification induces sensitivity to antiEGFR therapy in pancreatic acinar cell carcinoma. 61
29666669 2018
43
Imaging mimics of pancreatic ductal adenocarcinoma. 61
29038855 2018
44
Nomogram to Predict Cancer-Specific Survival in Patients with Pancreatic Acinar Cell Carcinoma: A Competing Risk Analysis. 61
30519311 2018
45
Successful chemotherapy with modified FOLFIRINOX for pancreatic acinar cell carcinoma. 61
29052123 2017
46
Pancreatic acinar cell carcinoma with extensive tumor embolism at the trunk of portal vein and pancreatic intraductal infiltration. 61
28921102 2017
47
Pancreatic acinar cell carcinoma: A review on molecular profiling of patient tumors. 61
29259370 2017
48
[A Difficult Diagnostic Case of Pancreatic Acinar Cell Carcinoma]. 61
29394592 2017
49
Genome-wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations in genome stability. 61
29109526 2017
50
Acinar cell carcinoma of the pancreas presenting as diffuse pancreatic enlargement: Two case reports and literature review. 61
28930825 2017

Variations for Pancreatic Acinar Cell Adenocarcinoma

Expression for Pancreatic Acinar Cell Adenocarcinoma

Search GEO for disease gene expression data for Pancreatic Acinar Cell Adenocarcinoma.

Pathways for Pancreatic Acinar Cell Adenocarcinoma

Pathways related to Pancreatic Acinar Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.27 SND1 KRAS HRAS
2 10.68 KRAS HRAS
3 10.6 KRAS HRAS
4 10.46 KRAS HRAS
5 9.74 KRAS HRAS

GO Terms for Pancreatic Acinar Cell Adenocarcinoma

Cellular components related to Pancreatic Acinar Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.02 SYP REG1A HRAS CHGA BCL10

Biological processes related to Pancreatic Acinar Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.33 KRAS HRAS BCL10
2 response to isolation stress GO:0035900 8.96 KRAS HRAS
3 regulation of long-term neuronal synaptic plasticity GO:0048169 8.8 SYP KRAS HRAS

Molecular functions related to Pancreatic Acinar Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex binding GO:0044877 8.92 KRT19 KRAS HRAS BCL10

Sources for Pancreatic Acinar Cell Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....